



ASX Release
21st May 2025

Correction re todays announcement -
\$1M Somfit Sale to World Leading Pharmaceutical Contract
Research Organisation in USA

Compumedics Limited (ASX: CMP) a global medical device Company that develops, manufactures and commercialises diagnostic technology for sleep, brain, and ultrasonic blood flow monitoring advises the last paragraph in today's announcement referred to guidance for FY26, but this was guidance for FY25.

The corrected paragraph is:

As a result, the Company continues to expect sales orders taken to be more than \$60m for FY25, with reported revenues (shipped and invoiced) lagging sales orders taken, as the Company adjusts for the significant growth in the business, particularly in the USA. As a result, the Company now expects reported revenues to be between \$50m and \$55m for **FY25**. This will be below the \$55m previously advised. EBITDA, as a result, is expected to be about \$3m, compared to \$5m as previously advised.

Further, the Company confirms FY26 revenue guidance of at least \$70m, as the Company will ship at least two of the three MEG orders currently on hand during FY26. This will result in EBITDA for FY26 being at least \$9m.

About Compumedics Limited

Compumedics Limited [ASX: CMP] is a medical device company that develops, manufactures, and commercialises diagnostic technology for sleep, brain, and ultrasonic blood flow monitoring applications. The Company owns Neuroscan, based in the US, and DWL Elektronische GmbH, based in Germany. In conjunction with these two subsidiaries, Compumedics has a broad international reach, including the Americas, Australia and Asia Pacific, Europe, and the Middle East.

Executive Chairman Dr. David Burton founded Compumedics in 1987. The same year, the Company successfully designed and installed the first fully computerised Australian sleep clinic at Epworth Hospital in Melbourne. Following this early success, Compumedics focused on developing products for the growing international sleep clinic and home monitoring markets.

Compumedics listed on the Australian Securities Exchange in 2000. Over the years, Compumedics has received numerous awards, including Australia's Exporter of the Year, and has been recognised as a Top 100 Innovator by both German and Australian Governments.

For personal use only

For further information, please contact:

Dr. David Burton
Executive Chairman, CEO

P: +61 3 8420 7300

F: +61 3 8420 7399

David Lawson

Director, CFO

P: + 61 3 8420 7300

F: +61 3 8420 7399

Authorised for lodgement by Compumedics Limited's Board of Directors

For personal use only